Vasoactive intestinal peptide, or VIP, has biological roles that have motivated research in several disease settings. Aviptadil is a synthetic VIP preparation studied clinically. A plausible mechanism can justify a trial, but the trial’s result must determine what can be claimed about benefit.

In the randomized TESICO study of hospitalized patients with COVID-19-associated hypoxemic respiratory failure, intravenous aviptadil did not improve the primary outcome or survival at day 90 compared with placebo. This result is important even though earlier observations and biological arguments had supported investigation. TESICO randomized aviptadil trial

Negative results are useful evidence

A well-conducted trial that does not demonstrate benefit narrows uncertainty. It prevents a promising hypothesis from being repeated as an established treatment claim. The result should not disappear from a research guide simply because positive studies are easier to summarize.

At the same time, a negative result in one disease and formulation does not prove that a molecule has no possible biological or therapeutic role anywhere. The correct interpretation stays with the tested population, intervention and endpoint.

Keep route and condition attached to the evidence

Intravenous, inhaled and other formulations cannot be treated as interchangeable. Different disease stages and background treatments can also influence the research question. If another study reports a different result, compare those details before concluding that one study “cancels” the other.

For a complete evidence assessment, look at trial size, prespecified analyses, treatment discontinuation and harms as well as the headline endpoint. A laboratory rationale and a small exploratory signal are weaker foundations for a clinical claim than a robust confirmatory result.

AXON’s VIP overview emphasizes that research progress includes learning when an intervention does not improve the tested outcome. It does not recommend VIP for respiratory disease, wellness or any other unverified use, and it does not treat research-product availability as evidence of clinical suitability.